Gene therapy for krabbe disease: did it last?

NCT ID NCT06308718

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FBX-101 (gene therapy)

What this could lead to

If successful, this follow-up could show whether a single gene therapy infusion provides lasting safety and motor benefits for children with Krabbe disease.

What could go wrong

This is a tiny observational follow-up (only 2 participants) of an already terminated trial. It cannot prove effectiveness and may not apply to other patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRABBE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Krabbe disease lysosomal storage disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan Hospitals - Michigan Medicine

    Ann Arbor, Michigan, 48109, United States